Folkman's Legacy of Bold and Creative Thinking Endures
March 19th 2014During the course of a 74-year life cut short by his sudden death in 2008, Folkman changed the world repeatedly with bold ideas that ranged from implantable pacemakers and subcutaneous birth control to an entirely new field of medical study: how diseases like cancer recruit blood vessels from the body via angiogenesis.
New Paradigms Emerge for Translating Immunotherapy Into Broad Clinical Use
March 14th 2014Although breakthrough successes are generating a renaissance for anticancer immunotherapies, the framework for translating promising research results into clinical practice remains very much under construction.
Discovery Dilemma: Narrow "Superiority" Standard Is an Inferior Way to Evaluate Novel Therapies
February 27th 2014The lack of documented superiority in a given randomized oncology trial may not indicate the absence of clinical utility but rather the presence of equivalent favorable activity for each of the two agents.
PARP Inhibitor BMN 673 Advances in Breast Cancer Study
February 18th 2014As PARP inhibitors continue to emerge as a novel class of anticancer agents, BMN 673 has entered late-stage clinical development as a treatment for patients with locally advanced or metastatic breast cancer whose tumors test positive for germline BRCA1/2 mutations.